Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 5/2005

01.10.2005 | Review

Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer

Erschienen in: Breast Cancer Research | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

Estrogen and its receptor (ER) are critical for development and progression of breast cancer. This pathway is targeted by endocrine therapies that either block ER functions or deplete ER's estrogen ligand. While endocrine therapies are very effective, de novo and acquired resistance are still common. Laboratory and clinical data now indicate that bidirectional molecular crosstalk between nuclear or membrane ER and growth factor receptor pathways such as HER2/neu is involved in endocrine resistance. Preclinical data suggest that blockade of selected growth factor receptor signaling can overcome this type of resistance, and this strategy is already being tested in clinical trials
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Beatson GT: On the treatment of inoperable cases of carcinogen of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896, 2: 104-107. 162-167.CrossRef
2.
Osborne CK, Zhao H, Fuqua SA: Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 2000, 18: 3172-3186.CrossRefPubMed
3.
Howell A, Osborne CK, Morris C, Wakeling AE: ICI 182,780 (Faslodex): development of a novel, 'pure' antiestrogen. Cancer. 2000, 89: 817-825. 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6.CrossRefPubMed
4.
Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005, 23: 619-629. 10.1200/JCO.2005.09.121.CrossRefPubMed
5.
Howell A, Dowsett M: Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res. 2004, 6: 269-274. 10.1186/bcr945.CrossRefPubMedPubMedCentral
6.
Osborne CK, Fuqua SA: Mechanisms of tamoxifen resistance. Breast Cancer Res Treat. 1994, 32: 49-55. 10.1007/BF00666205.CrossRefPubMed
7.
Carlson RW: Sequencing of endocrine therapies in breast cancer–integration of recent data. Breast Cancer Res Treat. 2002, 75: S27-S32. 10.1023/A:1020361700012. discussion S33-S25.CrossRefPubMed
8.
Parker MG: Steroid and related receptors. Curr Opin Cell Biol. 1993, 5: 499-504. 10.1016/0955-0674(93)90016-J.CrossRefPubMed
9.
Mosselman S, Polman J, Kijkema R: Identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996, 392: 49-53. 10.1016/0014-5793(96)00782-X.CrossRefPubMed
10.
Schiff R, Fuqua SAW: The importance of the estrogeb receptor in breast cancer. Breast Cancer: Prognosis, Treatment, and Prevention. Edited by: Pasqualini JR. 2002, New York, Basel: Marcel Dekker, Inc, 149-186.CrossRef
11.
Osborne CK, Schiff R, Fuqua SAW, Shou J: Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001, 7: 4338-4342.
12.
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995, 270: 1491-1494.CrossRefPubMed
13.
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998, 95: 927-937. 10.1016/S0092-8674(00)81717-1.CrossRefPubMed
14.
Bocchinfuso WP, Korach KS: Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia. 1997, 2: 323-334. 10.1023/A:1026339111278.CrossRefPubMed
15.
Allred DC, Mohsin SK, Fuqua SA: Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer. 2001, 8: 47-61. 10.1677/erc.0.0080047.CrossRefPubMed
16.
Hopp TA, Weiss H, Parra I, Cui Y, Osborne CK, Fuqua SA: Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004, 10: 7490-7499.CrossRefPubMed
17.
Nemere I, Pietras RJ, Blackmore PF: Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem. 2003, 88: 438-445. 10.1002/jcb.10409.CrossRefPubMed
18.
McKenna NJ, Nawaz Z, Tsai SY, Tsai M-J, O'Malley BW: Distinct steady-state nuclear receptor coregulator complexes exist in vivo. Proc Natl Acad Sci USA. 1998, 95: 11697-11702. 10.1073/pnas.95.20.11697.CrossRefPubMedPubMedCentral
19.
Dobrzycka KM, Townson SM, Jiang S, Oesterreich S: Estrogen receptor corepressors: a role in human breast cancer?. Endocr Relat Cancer. 2003, 10: 517-536. 10.1677/erc.0.0100517.CrossRefPubMed
20.
McKenna NJ, Lanz RB, O'Malley BW: Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev. 1999, 20: 321-344. 10.1210/er.20.3.321.PubMed
21.
Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L: Nuclear receptor coactivators and corepressors. Mol Endocrinol. 1996, 10: 1167-1177. 10.1210/me.10.10.1167.PubMed
22.
Fuqua SAW, Schiff R: The biology of estrogen receptors. Diseases of the Breast. Edited by: Harris JR, Lippman ME, Morrow M, Osborne CK. 2004, Philadelphia, PA: Lippincott Williams & Wilkins, 585-602. 3
23.
Torres-Arzayus MI, De Mora JF, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR, Brown M: High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell. 2004, 6: 263-274. 10.1016/j.ccr.2004.06.027.CrossRefPubMed
24.
List HJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A, Riegel AT: Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem. 2001, 276: 23763-23768. 10.1074/jbc.M102397200.CrossRefPubMed
25.
Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997, 277: 965-968. 10.1126/science.277.5328.965.CrossRefPubMed
26.
Bouras T, Southey MC, Venter DJ: Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res. 2001, 61: 903-907.PubMed
27.
Smith CL, Nawaz Z, O'Malley BW: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol. 1997, 11: 657-666. 10.1210/me.11.6.657.CrossRefPubMed
28.
Takimoto GS, Graham JD, Jackson TA, Tung L, Powell RL, Horwitz LD, Horwitz KB: Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J Steroid Biochem Mol Biol. 1999, 69: 45-50. 10.1016/S0960-0760(98)00148-4.CrossRefPubMed
29.
Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004, 96: 926-935.CrossRefPubMed
30.
Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P: Estrogen receptor pathways to AP-1. Steroid Biochem Mol Biol. 2000, 74: 311-317. 10.1016/S0960-0760(00)00108-4.CrossRef
31.
Safe S: Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm. 2001, 62: 231-252.CrossRefPubMed
32.
Xing W, Archer TK: Upstream stimulatory factors mediate estrogen receptor activation of the cathepsin D promoter. Mol Endocrinol. 1998, 12: 1310-1321. 10.1210/me.12.9.1310.CrossRefPubMed
33.
Ray P, Ghosh SK, Zhang DH, Ray A: Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Lett. 1997, 409: 79-85. 10.1016/S0014-5793(97)00487-0.CrossRefPubMed
34.
Sanchez R, Nguyen D, Rocha W, White JH, Mader S: Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays. 2002, 24: 244-254. 10.1002/bies.10066.CrossRefPubMed
35.
Wang F, Duan R, Chirgwin J, Safe SH: Transcriptional activation of cathepsin D gene expression by growth factors. J Mol Endocrinol. 2000, 24: 193-202. 10.1677/jme.0.0240193.CrossRefPubMed
36.
Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH: Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002, 21: 7680-7689. 10.1038/sj.onc.1205883.CrossRefPubMed
37.
Schiff R, Massarweh S, Shou J, Osborne CK: Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003, 9: 447S-454S.PubMed
38.
Nicholson RI, McClelland RA, Robertson JF, Gee JM: Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer. 1999, 6: 373-387. 10.1677/erc.0.0060373.CrossRefPubMed
39.
Huynh H, Yang X, Pollak M: Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem. 1996, 271: 1016-1021. 10.1074/jbc.271.2.1016.CrossRefPubMed
40.
Lee AV, Cui X, Oesterreich S: Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res. 2001, 7: 4429s-4435s. discussion 4411s-4412s.PubMed
41.
42.
Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC: Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res. 1999, 5: 251-256.PubMed
43.
Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, et al: Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000, 92: 1926-1934. 10.1093/jnci/92.23.1926.CrossRefPubMed
44.
Smith CL, Conneely OM, O'Malley BW: Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proc Natl Acad Sci USA. 1993, 90: 6120-6124.CrossRefPubMedPubMedCentral
45.
Aronica SM, Katzenellenbogen BS: Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol. 1993, 7: 743-752. 10.1210/me.7.6.743.PubMed
46.
Auricchio F, Di Domenico M, Migliaccio A, Castoria G, Bilancio A: The role of estradiol receptor in the proliferative activity of vanadate on MCF-7 cells. Cell Growth Differ. 1995, 6: 105-113.PubMed
47.
Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002, 2: 101-112. 10.1038/nrc721.CrossRefPubMed
48.
Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK: Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004, 10: 331S-336S.CrossRefPubMed
49.
Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem. 2001, 276: 9817-9824. 10.1074/jbc.M010840200.CrossRefPubMed
50.
Lee H, Jiang F, Wang Q, Nicosia SV, Yang J, Su B, Bai W: MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol Endocrinol. 2000, 14: 1882-1896. 10.1210/me.14.11.1882.PubMed
51.
Rogatsky I, Trowbridge JM, Garabedian MJ: Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem. 1999, 274: 22296-22302. 10.1074/jbc.274.32.22296.CrossRefPubMed
52.
Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, Taylor J, Epstein RJ, Fuller-Pace FV, Egly JM, et al: Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene. 2002, 21: 4921-4931. 10.1038/sj.onc.1205420.CrossRefPubMed
53.
Arnold SF, Obourn JD, Jaffe H, Notides AC: Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol Endocrinol. 1995, 9: 24-33. 10.1210/me.9.1.24.PubMed
54.
Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS: Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem. 1994, 269: 4458-4466.PubMed
55.
Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA: pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol. 1998, 18: 1978-1984.CrossRefPubMedPubMedCentral
56.
Wu RC, Qin J, Hashimoto Y, Wong J, Xu J, Tsai SY, Tsai MJ, O'Malley BW: Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase. Mol Cell Biol. 2002, 22: 3549-3561. 10.1128/MCB.22.10.3549-3561.2002.CrossRefPubMedPubMedCentral
57.
Wu RC, Qin J, Yi P, Wong J, Tsai SY, Tsai MJ, O'Malley BW: Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell. 2004, 15: 937-949. 10.1016/j.molcel.2004.08.019.CrossRefPubMed
58.
Ali S, Metzger D, Bornert JM, Chambon P: Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J. 1993, 12: 1153-1160.PubMedPubMedCentral
59.
Chen D, Pace PE, Coombes RC, Ali S: Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol. 1999, 19: 1002-1015.CrossRefPubMedPubMedCentral
60.
Lee H, Bai W: Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol. 2002, 22: 5835-5845. 10.1128/MCB.22.16.5835-5845.2002.CrossRefPubMedPubMedCentral
61.
Font de Mora J, Brown M: AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol. 2000, 20: 5041-5047. 10.1128/MCB.20.14.5041-5047.2000.CrossRefPubMedPubMedCentral
62.
Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, et al: Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA. 1998, 95: 2920-2925. 10.1073/pnas.95.6.2920.CrossRefPubMedPubMedCentral
63.
Hong SH, Privalsky ML: The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. Mol Cell Biol. 2000, 20: 6612-6625. 10.1128/MCB.20.17.6612-6625.2000.CrossRefPubMedPubMedCentral
64.
Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG: Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell. 2002, 110: 55-67. 10.1016/S0092-8674(02)00809-7.CrossRefPubMed
65.
Levin ER: Cellular functions of the plasma membrane estrogen receptor. Trends Endocrinol Metab. 1999, 10: 374-377. 10.1016/S1043-2760(99)00192-7.CrossRefPubMed
66.
Selye H: Correlations between the chemical structure and the pharmacological actions of the steroids. Endocrinology. 1942, 30: 437-453.CrossRef
67.
Razandi M, Pedram A, Greene GL, Levin ER: Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol. 1999, 13: 307-319. 10.1210/me.13.2.307.PubMed
68.
Pappas TC, Gametchu B, Watson CS: Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J. 1995, 9: 404-410.PubMed
69.
Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C: Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem. 2000, 275: 18447-18453. 10.1074/jbc.M910345199.CrossRefPubMed
70.
Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000, 407: 538-541. 10.1038/35035131.CrossRefPubMedPubMedCentral
71.
Morelli C, Garofalo C, Bartucci M, Surmacz E: Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells. Oncogene. 2003, 22: 4007-4016. 10.1038/sj.onc.1206436.CrossRefPubMed
72.
Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ: Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol. 2002, 16: 116-127. 10.1210/me.16.1.116.PubMed
73.
Anderson RG: The caveolae membrane system. Annu Rev Biochem. 1998, 67: 199-225. 10.1146/annurev.biochem.67.1.199.CrossRefPubMed
74.
Razandi M, Alton G, Pedram A, Ghonshani S, Webb P, Levin ER: Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol Cell Biol. 2003, 23: 1633-1646. 10.1128/MCB.23.5.1633-1646.2003.CrossRefPubMedPubMedCentral
75.
Razandi M, Pedram A, Park ST, Levin ER: Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem. 2003, 278: 2701-2712. 10.1074/jbc.M205692200.CrossRefPubMed
76.
Chung YL, Sheu ML, Yang SC, Lin CH, Yen SH: Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer. 2002, 97: 306-312. 10.1002/ijc.1614.CrossRefPubMed
77.
Vadlamudi RK, Wang RA, Mazumdar A, Kim Y, Shin J, Sahin A, Kumar R: Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J Biol Chem. 2001, 276: 38272-38279.PubMed
78.
Balasenthil S, Vadlamudi RK: Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem. 2003, 278: 22119-22127. 10.1074/jbc.M212822200.CrossRefPubMedPubMedCentral
79.
Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA. 2002, 99: 14783-14788. 10.1073/pnas.192569699.CrossRefPubMedPubMedCentral
80.
Xue Y, Wong J, Moreno GT, Young MK, Cote J, Wang W: NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol Cell. 1998, 2: 851-861. 10.1016/S1097-2765(00)80299-3.CrossRefPubMed
81.
Kumar R: Another tie that binds the MTA family to breast cancer. Cell. 2003, 113: 142-143. 10.1016/S0092-8674(03)00274-5.CrossRefPubMed
82.
Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1993, 24: 85-95.CrossRef
83.
Mass R: The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol. 2000, 27: 46-52. discussion 92-100.PubMed
84.
Ciocca DR, Elledge R: Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine. 2000, 13: 1-10. 10.1385/ENDO:13:1:1.CrossRefPubMed
85.
Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM: Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci. 2002, 963: 104-115.CrossRefPubMed
86.
Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/ neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003, 95: 353-361.CrossRefPubMed
87.
Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM: HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res. 2004, 10: 5670-5676.CrossRefPubMed
88.
Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001, 19: 3808-3816.CrossRefPubMed
89.
Smith IE, Dowsett M: Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res. 2003, 82: S6-
90.
Zhu L, Chow LW, Loo WT, Guan XY, Toi M: Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin Cancer Res. 2004, 10: 4639-4644.CrossRefPubMed
91.
Masamura S, Santner SJ, Heitjan DF, Santen RJ: Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab. 1995, 80: 2918-2925. 10.1210/jc.80.10.2918.PubMed
92.
Chu I, Blackwell K, Chen S, Slingerland J: The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005, 65: 18-25.PubMed
Metadaten
Titel
Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer
Publikationsdatum
01.10.2005
Erschienen in
Breast Cancer Research / Ausgabe 5/2005
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1287

Weitere Artikel der Ausgabe 5/2005

Breast Cancer Research 5/2005 Zur Ausgabe

Research article

A new option for early breast cancer patients previously irradiated for Hodgkin's disease: intraoperative radiotherapy with electrons (ELIOT)

Research article

Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells

Commentary

Treatment of solid tumors with immunotoxins

Research article

Epigenetic silencing of DSC3 is a common event in human breast cancer

Editorial

Overdiagnosis and breast cancer screening

Research article

Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise